<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557257</url>
  </required_header>
  <id_info>
    <org_study_id>B4531006</org_study_id>
    <nct_id>NCT01557257</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of ALO-02 and OxyContin</brief_title>
  <official_title>An Open-label, Single-dose and Multiple-dose, Randomized, Crossover Study to Evaluate Pharmacokinetics, Safety and Tolerability After Administration of ALO-02 40 Mg Twice Daily Compared to ALO-02 80 Mg Once Daily and to Oxycontin 40 Mg Twice Daily in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the
      administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice
      Daily in Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single-dose administration: Maximum Observed Plasma Concentration (Cmax) of oxycodone</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose administration: Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24) of oxycodone</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose administration: Time to Reach Maximum Observed Plasma Concentration (Tmax) of oxycodone</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Area under the plasma concentration versus time curve within a dosing interval of τ at steady state (AUCτ) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Maximum plasma concentration at steady state on Day 5 (Cmax,ss) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Minimum plasma concentration at steady state on Day 5 (Cmin,ss) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Average plasma concentration at steady state on Day 5 (Cave,ss) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Time to Reach Maximum Observed Plasma Concentration on Day 5 (Tmax) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Plasma Decay Half-Life (t1/2) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Peak to trough fluctuation at steady state (PTF) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose administration: Accumulation ratio based on Area Under Curve (AUC) (Rac) of oxycodone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-dose administration: Dose normalized Maximum Observed Plasma Concentration (Cmax(dn)) of oxycodone, noroxycodone, and oxymorphone.</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose administration: Dose-normalized Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24(dn)) of oxycodone, noroxycodone, and oxymorphone.</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose administration: Maximum Observed Plasma Concentration (Cmax) of noroxycodone and oxymorphone.</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose administration: Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24) of noroxycodone and oxymorphone.</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose administration: Time to Reach Maximum Observed Plasma Concentration (Tmax) of noroxycodone and oxymorphone.</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Accumulation ratio (Rac) of oxycodone, as data permit</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Maximum Observed Plasma Concentration (Cmax) of oxycodone, as data permit</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Area under the plasma concentration versus time curve within a dosing interval of τ (AUCτ) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Maximum plasma concentration at steady state (Cmax,ss) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Minimum plasma concentration at steady state (Cmin,ss) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Average plasma concentration at steady state (Cave,ss) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Time to Reach Maximum Observed Plasma Concentration (Tmax) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Plasma Decay Half-Life (t1/2) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Peak to trough fluctuation at steady state (PTF) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Rac of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose administration: Maximum Observed Plasma Concentration (Cmax) of noroxycodone and oxymorphone, as data permit.</measure>
    <time_frame>96,96.5,97,98,100,102,104,108,108.5,109,110,112,114,116,120,132,144,168 hours post Day 1 dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Management of Moderate to Severe Pain</condition>
  <arm_group>
    <arm_group_label>40 mg ALO-02 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg ALO-02 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg OxyContin tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02</intervention_name>
    <description>Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)</description>
    <arm_group_label>40 mg ALO-02 capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone block</intervention_name>
    <description>Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing</description>
    <arm_group_label>40 mg ALO-02 capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALO-02</intervention_name>
    <description>Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)</description>
    <arm_group_label>80 mg ALO-02 capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone block</intervention_name>
    <description>Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.</description>
    <arm_group_label>80 mg ALO-02 capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OxyContin</intervention_name>
    <description>Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)</description>
    <arm_group_label>40 mg OxyContin tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone block</intervention_name>
    <description>Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing</description>
    <arm_group_label>40 mg OxyContin tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

        Exclusion Criteria:

          -  Evidence or history of clinically significant diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531006&amp;StudyName=Pharmacokinetics%20Study%20of%20ALO-02%20and%20OxyContin%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>single- and multiple-dose pharmacokinetics</keyword>
  <keyword>ALO-02</keyword>
  <keyword>OxyContin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

